GlassScriptPhysician profile
David P Visco
NPI 1104961564
$9,571.14
in general payments reported to CMS, 2019-2025
40 companies · $2,999 in 2025
The $2,999 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $171 · 2021: $453 · 2022: $1,516 · 2023: $1,827 · 2024: $2,194 · 2025: $2,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,818 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,817.52 |
| Education | $201.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,325.41 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,310.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $830.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $699.96 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $482.97 | 2021-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $298.31 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $280.47 | 2024-2025 | Lumryz |
| Insmed, INC. | $264.07 | 2022-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $251.97 | 2022-2025 | Aralast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.21 | 2019-2025 | Ofev |
| Axsome Therapeutics, INC. | $235.58 | 2023-2025 | Sunosi |
| Amgen INC. | $217.02 | 2022-2025 | Tezspire |
| Philips North America LLC | $196.87 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genentech USA, INC. | $188.35 | 2021-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $181.00 | 2023-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Broncus Medical | $177.07 | 2019 | |
| Mylan Specialty L.P. | $173.34 | 2019-2024 | Yupelri |
| Electromed, INC. | $150.97 | 2022-2025 | Smartvest |
| Verona Pharma, INC. | $141.60 | 2025 | Ohtuvayre |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Viatris Specialty LLC | $108.36 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $91.26 | 2023-2024 | Purified Cortrophin Gel |
| Resmed Corp | $86.56 | 2020-2025 | |
| United Therapeutics Corporation | $68.20 | 2024-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $62.82 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $45.59 | 2023-2024 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $35.34 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $33.37 | 2020-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $33.16 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $31.90 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.42 | 2023 | Lifevest |
| Optinose US, INC. | $29.80 | 2025 | |
| Jazz Pharmaceuticals INC. | $29.07 | 2021 | |
| Vapotherm INC | $24.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.21 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.20 | 2023 | Xarelto |
| Lilly USA, LLC | $17.00 | 2025 | Zepbound |
| Kyowa Kirin, INC. | $15.88 | 2025 | |
| Shire North American Group INC | $14.87 | 2019 | |
| Invivyd INC | $13.98 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Visco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.